L26/P-687 Freeze-all versus fresh blastocyst transfer in GnRH antagonist cycles with elevated progesterone on trigger day: a randomised controlled trial
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Z. Shi und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question In women with progesterone ≥1.2 ng/mL on trigger day, does freeze-all improve pregnancy rates and cost-effectiveness versus fresh blastocyst transfer? Summary answer Freeze-all significantly improved clinical pregnancy rates but at higher cost versus fresh transfer in GnRH antagonist cycles with progesterone ≥ 1.2 ng/mL What is known already Elevated late-follicular progesterone impairs endometrial receptivity and reduces fresh IVF success. Many clinicians adopt freeze-all, yet evidence stems from heterogeneous studies mixing cleavage- and blastocyst-stage transfers. Blastocyst culture may mitigate embryo–endometrial asynchrony, but our prior retrospective data showed lower live birth after fresh blastocyst transfer when progesterone ≥1.2 ng/mL. Prospective, blastocyst-specific randomised trials evaluating both efficacy and cost-effectiveness in this subgroup are lacking. Study design, size, duration This open-label, parallel-group randomised controlled trial enrolled 780 women at a tertiary IVF centre in China between February 2023 and October 2025. Participants were randomised 1:1 on hCG trigger day to either freeze-all with deferred frozen blastocyst transfer or immediate fresh blastocyst transfer. Participants/materials, setting, methods Women <38 years, undergoing first IVF/ICSI with GnRH antagonist protocol, yielding ≥1 blastocyst, and progesterone ≥1.2 ng/mL on trigger day were included. Exclusion: progesterone ≥3.0 ng/ml, uterine/endocrine pathology, stage III–IV endometriosis, PGT or OHSS risk. In the freeze-all group, all blastocysts were vitrified and subsequently transferred in the frozen cycle. Primary outcome is live birth; interim analysis reports clinical pregnancy rate per transfer. Direct medical costs to first transfer were assessed. All analyses followed intention-to-treat. Main results and the role of chance Clinical pregnancy occurred in 254/386 (65.8%) women in the freeze-all group versus 231/394 (58.6%) in the fresh group (risk ratio [RR] 1.12, 95% CI 1.01–1.25; P = 0.039), corresponding to an absolute risk difference of 7.2 percentage points and a number needed to treat of 14. Biochemical pregnancy rates were also higher with freeze-all (72.0% vs. 64.5%; RR 1.12, 95% CI 1.02–1.23; P = 0.024). Miscarriage rates did not differ significantly (12.2% vs. 13.0%; RR 0.94, 95% CI 0.65–1.36; P = 0.745). The incremental cost per additional clinical pregnancy achieved with freeze-all was ¥4,117–9,374 (≈ $ 589–1,341). Per-protocol analyses yielded consistent results. Limitations, reasons for caution This single-center trial was conducted in China; results may not generalize to settings with different progesterone thresholds, laboratory protocols, or healthcare cost structures. Additionally, live birth, our pre-specified primary outcome is pending and will be reported in the final analysis. Wider implications of the findings Freeze-all modestly improves clinical pregnancy at added cost when progesterone is ≥ 1.2 ng/mL. Given limited cost-effectiveness under current Chinese pricing, universal freeze-all cannot be justified. Decisions should be individualised, considering prognosis, patient preferences, and financial implications rather than driven by routine policy. Trial registration number Yes
Zitieren
APA
Shi, Z., Cai, H., Zhang, D., Li, W., Xue, X., & Shi, J. (2026). L26/P-687 Freeze-all versus fresh blastocyst transfer in GnRH antagonist cycles with elevated progesterone on trigger day: a randomised controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1017
Vancouver
Shi Z, Cai H, Zhang D, Li W, Xue X, Shi J. L26/P-687 Freeze-all versus fresh blastocyst transfer in GnRH antagonist cycles with elevated progesterone on trigger day: a randomised controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1017
BibTeX
@article{Shi2026,
author = {Shi, Z. and Cai, H. and Zhang, D. and Li, W. and Xue, X. and Shi, J.},
title = {L26/P-687 Freeze-all versus fresh blastocyst transfer in GnRH antagonist cycles with elevated progesterone on trigger day: a randomised controlled trial},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1017}
}
EUVIMED